TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26918330

Group type: EXPERIMENTAL
Intervention: Saccharomyces boulardii (probiotic)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 39
Study: 24792735

Group type: EXPERIMENTAL
Intervention: GIK
Number of subjects: 871

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 871
Study: 21707914

Group type: EXPERIMENTAL
Intervention: Intracoronary autologous freshly isolated bone marrow cells transplantation (BMCs‐Tx)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group without cell therapy
Number of subjects: 62
Study: 19545209

Group type: EXPERIMENTAL
Intervention: Circumcision
Number of subjects: 2655

Group type: COMPARATOR
Intervention: Control (uncircumcised)
Number of subjects: 2655
Study: 17293188

Group type: EXPERIMENTAL
Intervention: Folic acid (10 mg/day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Nitroglycerin
Number of subjects: 40
Study: 15223093

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 11213857

Group type: EXPERIMENTAL
Intervention: Budesonide inhalation suspension (BIS)
Number of subjects: 0
Study: 9860783

Group type: EXPERIMENTAL
Intervention: GP IIb/IIIa inhibitors
Number of subjects: 32135
Study: 7979853

Group type: EXPERIMENTAL
Intervention: Nicotine nasal spray (0.5 mg per single spray)
Number of subjects: 248

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Nicotine nasal spray
Number of subjects: 248
Study: 2472275

Group type: EXPERIMENTAL
Intervention: MFL (methotrexate-5-FU with leucovorin rescue)
Number of subjects: 44

Group type: COMPARATOR
Intervention: 5-FU (5-fluorouracil)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: MFL
Number of subjects: 44

Group type: COMPARATOR
Intervention: 5-FU
Number of subjects: 44
Study: 4916870

Group type: EXPERIMENTAL
Intervention: Levamisole (single oral dose)
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Levamisole (single dose)
Number of subjects: 211

Group type: COMPARATOR
Intervention: Piperazine citrate (single dose)
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 211
Study: 29072026

Group type: EXPERIMENTAL
Intervention: Kinesio taping
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard orthotics
Number of subjects: 40
Study: 27998967

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 51
Study: 26188932

Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine gel
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: eugenol-based paste
Number of subjects: 270

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 270
Study: 23294685

Group type: EXPERIMENTAL
Intervention: High-velocity low-amplitude thrust (HVLAT)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Sham functional technique (SFT)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Sham ultrasound (SUS)
Number of subjects: 10

Group type: COMPARATOR
Intervention: No intervention control (NIC)
Number of subjects: 10
Study: 21978211

Group type: EXPERIMENTAL
Intervention: Sodium hyaluronate (Hyalgan®)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 17693145

Group type: EXPERIMENTAL
Intervention: L-Carnitine (2 g daily for 180 days)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 14684587

Group type: EXPERIMENTAL
Intervention: Interferon alfa, ribavirin, and amantadine
Number of subjects: 171

Group type: COMPARATOR
Intervention: Interferon alfa and ribavirin
Number of subjects: 171
Study: 12134281

Group type: EXPERIMENTAL
Intervention: Pergolide (2.25 mg/day)
Number of subjects: 1

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1
Study: 9813510

Group type: EXPERIMENTAL
Intervention: Diamorphine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 40
Study: 7656739

Group type: EXPERIMENTAL
Intervention: Passive drainage (PD)
Number of subjects: 186

Group type: COMPARATOR
Intervention: Closed suction drainage (SD)
Number of subjects: 186
Study: 2682242

Group type: EXPERIMENTAL
Intervention: Carbon monoxide exposure (117 +/- 4.4 ppm)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Carbon monoxide exposure (253 +/- 6.1 ppm)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Room air (control)
Number of subjects: 63
Study: 15762

Group type: EXPERIMENTAL
Intervention: Propranolol (40 mg thrice daily with meals)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Prindolol (5 mg thrice daily with meals)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Methyclothiazide (5 mg with breakfast)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Propranolol doses (120 mg, 60 mg, 40 mg with meals)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Metoprolol (200 mg with breakfast, 100 mg with breakfast and evening meal)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Prindolol (30 mg, 15 mg, 10 mg with meals)
Number of subjects: 9
Study: 31368283

Group type: EXPERIMENTAL
Intervention: Blade needle therapy (longitudinal cutting along the musculoaponeurotic layer) applied to tender points of the head and neck, treatment conducted once every 3 days for 15 days.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Medication group receiving Flunarizine Hydrochloride capsules (10 mg) once every night for 15 days.
Number of subjects: 60
Study: 27804900

Group type: EXPERIMENTAL
Intervention: ROTATE (n = 53)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Waiting-list control (WLC) (n = 33)
Number of subjects: 86
Study: 25944513

Group type: EXPERIMENTAL
Intervention: Hypocapnia trial (voluntary hyperventilation, minute ventilation = 31 L min(‐1))
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control trial (spontaneous breathing, minute ventilation = 14 L min(‐1))
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Hypocapnia trial
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control trial
Number of subjects: 9
Study: 22854773

Group type: EXPERIMENTAL
Intervention: Participatory return-to-work (RTW) program
Number of subjects: 163

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 163
Study: 21971743

Group type: EXPERIMENTAL
Intervention: Sitting up for five minutes after spinal anesthesia (Group S)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Lying down immediately after spinal anesthesia (Group L)
Number of subjects: 120
Study: 19463339

Group type: EXPERIMENTAL
Intervention: Intracellular calcium modulator as adjunct to primary PCI
Number of subjects: 378
Study: 16491425

Group type: EXPERIMENTAL
Intervention: 111In-DOTA-TOC
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 111In-DOTA-LAN
Number of subjects: 45
Study: 15120774

Group type: EXPERIMENTAL
Intervention: Valdecoxib 40 mg
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Rofecoxib 50 mg
Number of subjects: 250

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study: 11275926

Group type: EXPERIMENTAL
Intervention: abciximab
Number of subjects: 6519

Group type: COMPARATOR
Intervention: smoking status
Number of subjects: 6519
Study: 9831269

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Omeprazole 20 mg
Number of subjects: 8
Study: 7862803

Group type: EXPERIMENTAL
Intervention: Smokers (885)
Number of subjects: 6900

Group type: COMPARATOR
Intervention: Nonsmokers (6,015)
Number of subjects: 6900
Study: 2571021

Group type: EXPERIMENTAL
Intervention: GHB (50 mg/kg, orally in a syrup preparation)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control syrup (no active treatment)
Number of subjects: 23
Study: 1277749

Group type: EXPERIMENTAL
Intervention: Arginine vasopressin infusion at 12.5 units/min for 1 h
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Arginine vasopressin infusion at 25 units/min for 1 h
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Arginine vasopressin infusion (both doses)
Number of subjects: 7
Study: 31987677

Group type: EXPERIMENTAL
Intervention: Surgical simulator training (30 hours)
Number of subjects: 12

Group type: COMPARATOR
Intervention: No simulator training
Number of subjects: 12
Study: 31423869

Group type: EXPERIMENTAL
Intervention: Systolic blood pressure target of <130 mm Hg
Number of subjects: 3020

Group type: COMPARATOR
Intervention: Systolic blood pressure target of 130 to 149 mm Hg
Number of subjects: 3020
Study: 27978602

Group type: EXPERIMENTAL
Intervention: Immediate Implant (IMI)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Delayed Implant (DI)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Patient reported outcomes
Number of subjects: 124
Study: 26231756

Group type: EXPERIMENTAL
Intervention: Active rehabilitation intervention (low-intensity exercise programme consisting of aerobic, coordination and visualisation exercises)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care education group
Number of subjects: 0
Study: 23591282

Group type: EXPERIMENTAL
Intervention: Botulinum toxin (BTX) injections (8 × 12.5 U)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Saline injections (8 × 0.5 mL)
Number of subjects: 22
Study: 20926105

Group type: EXPERIMENTAL
Intervention: Minimally invasive repair via right minithoracotomy (MI group)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Conventional open repair via median sternotomy (MS group)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Both groups (MI and MS)
Number of subjects: 70
Study: 19901006

Group type: EXPERIMENTAL
Intervention: Combined sexual and alcohol risk reduction (GPI + GMET)
Number of subjects: 484

Group type: EXPERIMENTAL
Intervention: Sexual risk reduction only (GPI)
Number of subjects: 484

Group type: COMPARATOR
Intervention: HIV/sexually transmitted disease prevention information only (GINFO)
Number of subjects: 484

Group type: EXPERIMENTAL
Intervention: GPI + GMET
Number of subjects: 484
Study: 16450086

Group type: EXPERIMENTAL
Intervention: Aprepitant (A) regimen: A 125 mg p.o. plus ondansetron (O) 32 mg and dexamethasone (D) 12 mg on day 1; A 80 mg and D 8 mg once daily on days 2-3; and D 8 mg on day 4.
Number of subjects: 1044

Group type: COMPARATOR
Intervention: Control regimen: Ondansetron (O) 32 mg i.v. and dexamethasone (D) 20 mg p.o. on day 1; D 8 mg twice daily on days 2-4.
Number of subjects: 1044

Group type: EXPERIMENTAL
Intervention: Aprepitant (A) regimen
Number of subjects: 1044

Group type: COMPARATOR
Intervention: Control regimen
Number of subjects: 1044
Study: 15223402

Group type: EXPERIMENTAL
Intervention: No retransfusion of cardiotomy suction blood and mediastinal shed blood
Number of subjects: 29

Group type: COMPARATOR
Intervention: Retransfusion of cardiotomy suction blood and mediastinal shed blood
Number of subjects: 29
Study: 11723278

Group type: EXPERIMENTAL
Intervention: Interferon-beta1b (8 x 10(6) IU)
Number of subjects: 718

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 718
Study: 9140160

Group type: EXPERIMENTAL
Intervention: Low-dose UDCA (10 mg/kg/day)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: High-dose UDCA (20 mg/kg/day)
Number of subjects: 30
Study: 7963019

Group type: EXPERIMENTAL
Intervention: GELP synthesizer with glottal excitation codebook (32 entries) and stochastic codebook (256 entries) for unvoiced noise excitation.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GELP synthesizer
Number of subjects: 0
Study: 3300423

Group type: EXPERIMENTAL
Intervention: Subarachnoid lidocaine 1 mg/kg plus salmon calcitonin (sCT) 100 IU
Number of subjects: 60

Group type: COMPARATOR
Intervention: Subarachnoid lidocaine plus saline
Number of subjects: 60
Study: 31536766

Group type: EXPERIMENTAL
Intervention: 0.4% Î²G supplementation
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: 1/20 FP + 0.4% Î²G
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: 1/10 FP + 0.4% Î²G
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: 0.4% Î²G
Number of subjects: 270

Group type: COMPARATOR
Intervention: FP exposure
Number of subjects: 270
Study: 28540394

Group type: EXPERIMENTAL
Intervention: Two-year oral health programme
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90
Study: 26856306

Group type: EXPERIMENTAL
Intervention: Simple postal intervention highlighting the importance of maintaining asthma medication
Number of subjects: 0
Study: 24499161

Group type: EXPERIMENTAL
Intervention: Healthy Active Living (HAL) community intervention
Number of subjects: 60

Group type: COMPARATOR
Intervention: No-treatment control residence
Number of subjects: 60
Study: 22152079

Group type: EXPERIMENTAL
Intervention: Hyperoxia (FIO(2) = 0.4)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Normoxia
Number of subjects: 20
Study: 19618788

Group type: EXPERIMENTAL
Intervention: Postpartum relapse prevention interventions that address SHS exposure
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Comprehensive intervention prioritizing parental education on SHS effects, empowerment to remain abstinent, and adoption of smoke-free home policy
Number of subjects: 11
Study: 17495782

Group type: EXPERIMENTAL
Intervention: Curare (cholinergic blockade)
Number of subjects: 20

Group type: COMPARATOR
Intervention: No curare (control group)
Number of subjects: 20
Study: 15708844

Group type: EXPERIMENTAL
Intervention: 900 mg/day hypericum extract WS 5570 three times a day for six weeks
Number of subjects: 251

Group type: COMPARATOR
Intervention: 20 mg paroxetine once a day for six weeks
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: hypericum extract WS 5570
Number of subjects: 251

Group type: COMPARATOR
Intervention: paroxetine
Number of subjects: 251
Study: 12408204

Group type: EXPERIMENTAL
Intervention: Standard behavioral treatment group including a couples intervention
Number of subjects: 160

Group type: COMPARATOR
Intervention: Standard behavioral treatment group
Number of subjects: 160
Study: 9583482

Group type: EXPERIMENTAL
Intervention: TRAM flap
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Latissimus dorsi flap
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lateral thoracodorsal flap
Number of subjects: 0

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 0
Study: 7657029

Group type: EXPERIMENTAL
Intervention: Hyperinsulinemic euglycemic clamp (plasma insulin concentration 586 +/- 9.7 pmol/l) for 13 hours
Number of subjects: 7

Group type: COMPARATOR
Intervention: Saline infusion for 13 hours (control)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Hyperinsulinemic euglycemic clamp
Number of subjects: 7
Study: 2652546

Group type: EXPERIMENTAL
Intervention: Aza and Pred (Group I)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: CyA alone (Group II)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: CyA and steroids (Group III)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Aza (previous study)
Number of subjects: 48
Study: 791585

Group type: COMPARATOR
Intervention: Indomethacin (150 mg/day) plus placebo
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Indomethacin (150 mg/day) plus proglumide (900 mg/day)
Number of subjects: 32
Study: 31180155

Group type: COMPARATOR
Intervention: Control CL (single vision, silicone hydrogel contact lenses)
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: Test CL I (myopic defocus +1.00D centrally and +2.50D at 3 mm semi-chord)
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: Test CL II (myopic defocus +1.00D centrally and +1.50D at 3 mm semi-chord)
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: Test CL III (EDOF hydrogel CL with extended depth of focus +1.75D)
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: Test CL IV (EDOF hydrogel CL with extended depth of focus +2.50D)
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: Test CL (compliant wearers ≥6 days per week)
Number of subjects: 508
Study: 28677982

Group type: EXPERIMENTAL
Intervention: Triglyceride (TG) alone
Number of subjects: 1994

Group type: EXPERIMENTAL
Intervention: Triglyceride (TG) in combination with waist circumference (WC)
Number of subjects: 1994

Group type: EXPERIMENTAL
Intervention: Overweight in women
Number of subjects: 1994

Group type: EXPERIMENTAL
Intervention: Obesity in women
Number of subjects: 1994

Group type: EXPERIMENTAL
Intervention: Overweight in men
Number of subjects: 1994

Group type: EXPERIMENTAL
Intervention: Obesity in men
Number of subjects: 1994

Group type: EXPERIMENTAL
Intervention: Unhealthy diet in women
Number of subjects: 1994

Group type: EXPERIMENTAL
Intervention: Weekly Cola consumption in women
Number of subjects: 1994

Group type: EXPERIMENTAL
Intervention: Impaired glucose tolerance in women
Number of subjects: 1994
Study: 25461685

Group type: EXPERIMENTAL
Intervention: 3D laparoscopy
Number of subjects: 30

Group type: COMPARATOR
Intervention: 2D laparoscopy
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Preference
Number of subjects: 30
Study: 24617605

Group type: EXPERIMENTAL
Intervention: Pitavastatin (1 mg) with rifampicin (600 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Rosuvastatin (5 mg) with rifampicin (600 mg)
Number of subjects: 16
Study: 22733794

Group type: EXPERIMENTAL
Intervention: Self-managed computer treatment with volunteer support
Number of subjects: 34

Group type: COMPARATOR
Intervention: Usual care (everyday language activity)
Number of subjects: 34
Study: 19540443

Group type: EXPERIMENTAL
Intervention: 10% formalin (group A)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: 3% sodium azide (group B)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Distilled water (group C)
Number of subjects: 66
Study: 17470740

Group type: EXPERIMENTAL
Intervention: Tamoxifen (20 mg daily)
Number of subjects: 5408

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5408
Study: 15697102

Group type: EXPERIMENTAL
Intervention: Contraceptive vaginal ring (NuvaRing) delivering 15 microg ethinylestradiol and 120 microg etonogestrel per day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Combined oral contraceptive containing 30 microg ethinylestradiol and 150 microg levonorgestrel
Number of subjects: 0
Study: 16158750

Group type: EXPERIMENTAL
Intervention: Trospium chloride (15 mg/day, titrated to a maximum of 45 mg)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Trospium chloride (30 mg and then 45 mg/day for 3 patients)
Number of subjects: 66
Study: 10227614

Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 9074901

Group type: EXPERIMENTAL
Intervention: Calcium carbonate plus magnesium carbonate (Rennie)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Hydrotalcite (Talcid)
Number of subjects: 12
Study: 1653137

Group type: EXPERIMENTAL
Intervention: 100 mg sumatriptan
Number of subjects: 1130

Group type: EXPERIMENTAL
Intervention: 200 mg sumatriptan
Number of subjects: 1130

Group type: EXPERIMENTAL
Intervention: 300 mg sumatriptan
Number of subjects: 1130

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1130

Group type: EXPERIMENTAL
Intervention: All active treatment groups (100 mg, 200 mg, 300 mg sumatriptan)
Number of subjects: 1130

Group type: EXPERIMENTAL
Intervention: Sumatriptan (all doses)
Number of subjects: 1130
Study: 6684027

Group type: EXPERIMENTAL
Intervention: NH4Cl (ammonium chloride) group
Number of subjects: 11

Group type: COMPARATOR
Intervention: CaCO3 (calcium carbonate) placebo control group
Number of subjects: 11
Study: 30552060

Group type: COMPARATOR
Intervention: Cathodal tDCS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tyrosine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Combined administration of tyrosine with cathodal tDCS
Number of subjects: 0
Study: 29788418

Group type: EXPERIMENTAL
Intervention: Bezlotoxumab
Number of subjects: 1554

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1554
Study: 27501604

Group type: EXPERIMENTAL
Intervention: US-guided technique (US-group)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Palpation technique (P-group)
Number of subjects: 100
Study: 24218517

Group type: EXPERIMENTAL
Intervention: Cetuximab
Number of subjects: 572

Group type: COMPARATOR
Intervention: Best supportive care (BSC)
Number of subjects: 572
Study: 22634075

Group type: EXPERIMENTAL
Intervention: Hospital clinic group-based intervention
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Home-based intervention
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 110
Study: 20547639

Group type: EXPERIMENTAL
Intervention: MRI of the brain
Number of subjects: 953
Study: 18521048

Group type: EXPERIMENTAL
Intervention: Black cohosh (BC) treatment for 12 weeks at a standard dose (Remifemin, 40 mg/day)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Naloxone blockade
Number of subjects: 11

Group type: COMPARATOR
Intervention: Naloxone blockade during sleep
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Black cohosh treatment
Number of subjects: 11
Study: 16075684

Group type: EXPERIMENTAL
Intervention: Immunomodulator Vilon
Number of subjects: 0
Study: 12219998

Group type: EXPERIMENTAL
Intervention: Selective laser trabeculoplasty (SLT) using a frequency-doubled, Q-switched Nd:YAG laser (532 nm)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Selective laser trabeculoplasty (SLT)
Number of subjects: 20
Study: 10519894

Group type: EXPERIMENTAL
Intervention: Transplantation (myeloablative chemotherapy, total-body irradiation, and transplantation of autologous bone marrow)
Number of subjects: 379

Group type: COMPARATOR
Intervention: Continuation chemotherapy (intensive chemotherapy alone)
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: 13-cis-retinoic acid (isotretinoin) for six months
Number of subjects: 379

Group type: COMPARATOR
Intervention: No further therapy
Number of subjects: 379
Study: 8526187

Group type: COMPARATOR
Intervention: VAD (vincristine, doxorubicin, and dexamethasone)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: VAD plus interferon alfa-2
Number of subjects: 47

Group type: COMPARATOR
Intervention: VAD
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Both groups (VAD and VAD plus interferon)
Number of subjects: 47
Study: 1760422

Group type: EXPERIMENTAL
Intervention: GIFT
Number of subjects: 59

Group type: COMPARATOR
Intervention: IUI after ovarian hyperstimulation
Number of subjects: 59

Group type: COMPARATOR
Intervention: IUI in a spontaneous cycle
Number of subjects: 59
Study: 31442203

Group type: EXPERIMENTAL
Intervention: Achillea wilhelmsii C. Koch capsules
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 28650787

Group type: EXPERIMENTAL
Intervention: 1.23% APF gel
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: CPP‐ACP
Number of subjects: 60

Group type: COMPARATOR
Intervention: Artificial saliva
Number of subjects: 60